AXIOS October 31, 2023
Shawna Chen

The push to use psychedelics as treatment for veterans with PTSD is gaining momentum across the country — and the Bay Area is taking the lead.

Why it matters: Studies show that MDMAs reduce PTSD symptoms and functional impairment. Advocates are working to secure FDA approval of its use in a bid to more effectively tackle the suicide epidemic among veterans.

State of play: Veterans Affairs Palo Alto is gearing up to recruit and screen participants for its own clinical trials with MDMA-assisted therapy, according to Stanford psychiatry professor Trisha Suppes, who is overseeing the research.

  • Under current protocol, patients are administered the compound three times over a 12- to 14-week period in a controlled, supervised setting with therapists.
  • ...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Mental Health, Patient / Consumer, Provider, VA / DoD
It’s Time for Health Plans to Hold Behavioral Health Providers Accountable for Outcomes
Psychiatric Times Through the Years: The Last 5 Years in February Covers
First, do no harm: Now is the time to fight mental health stigma and advocate for residency reform
The Status of Child Psychiatric Research in 2025: Progress, Problems, and Prospects
5 Key Facts about Medicaid Coverage for Adults with Mental Illness

Share This Article